Möchten Sie immer auf dem neuesten Stand bleiben?

Hatteras Venture Partners honors HistoSonics with the Charles A. Sanders Award for Entrepreneurial Excellence

Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week

Ottawa, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The global radiopharmaceutical market size was valued at USD 6.8 billion in 2024 and is predicted to hit around USD 14.11 billion by 2034, rising at a 7.57%...

Adverse events (AEs) generally transient and readily manageable; only 2 cases of cytokine release syndrome (CRS)Prolonged tumor control with increasing doses of BA3182; confirmed partial response...

REDWOOD CITY, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing potentially life-changing therapeutics for...

– Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites – – Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed...

September 12, 2025 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage...

Bluejay Therapeutics enrolled the first patient in the AZURE-2 trial evaluating brelovitug (BJT-778) compared to Hepcludex (bulevirtide) in CHD.

Positive top-line results for VIBRANT Phase 2 clinical trial of verekitug in CRSwNP with once every 12 week dosing

New York, USA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Focal Segmental Glomerulosclerosis Clinical Trial Pipeline Analysis Demonstrates 12+ Key Companies at the Horizon Expected to Transform the Treatment...